comparemela.com

Latest Breaking News On - Miebo trxs - Page 1 : comparemela.com

Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month - Bausch & Lomb (NYSE:BLCO)

"Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins for 2024.

Sahil dhingraXiidra trxAlcon incDouglas miehmLomb corpMiebo trxsBenzinga proLomb expandsCare portfolioNew drug application

Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month

Eye health products company Bausch + Lomb Corp (NYSE:BLCO) is scheduled to release its fourth-quarter and full-year 2023 financial resul.

Xiidra trxDouglas miehmSahil dhingraMiebo trxsLomb corpAlcon incBenzinga proLomb expandsCare portfolioNew drug application

vimarsana © 2020. All Rights Reserved.